Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

7.65USD
15 Feb 2019
Change (% chg)

$0.39 (+5.37%)
Prev Close
$7.26
Open
$7.28
Day's High
$7.67
Day's Low
$7.19
Volume
39,736
Avg. Vol
49,403
52-wk High
$12.95
52-wk Low
$5.03

Latest Key Developments (Source: Significant Developments)

Minerva Neurosciences Announces Results Of Dose Escalation Study Evaluating Roluperidone
Monday, 19 Nov 2018 08:00am EST 

Nov 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES RESULTS OF DOSE ESCALATION STUDY EVALUATING ROLUPERIDONE (MIN-101) ADMINISTERED AT SUPRA-THERAPEUTIC DOSES IN HEALTHY VOLUNTEERS.MINERVA - ALL DOSES TESTED UP TO 256 MILLIGRAMS APPEAR SAFE, WELL TOLERATED WITH NO SIGNIFICANT CHANGES IN CARDIAC REPOLARIZATION AND QTC INTERVALS.MINERVA NEUROSCIENCES INC - IN DATA FROM TRIAL, NO SERIOUS ADVERSE EVENTS WERE REPORTED.MINERVA NEUROSCIENCES INC - IN TRIAL, NO SIGNIFICANT CHANGE IN REPOLARIZATION WAS OBSERVED..MINERVA NEUROSCIENCES INC - IN TRIAL, TWO SUBJECTS IN PLACEBO GROUP, NINE SUBJECTS IN ROLUPERIDONE GROUP REPORTED ADVERSE EVENTS.MINERVA NEUROSCIENCES INC - TOP-LINE RESULTS FROM 12-WEEK DOUBLE-BLIND PHASE OF PHASE 3 TRIAL ARE EXPECTED IN MID-2019.  Full Article

Minerva Neurosciences Qtrly Loss Per Share $0.31
Monday, 5 Nov 2018 07:30am EST 

Nov 5 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES.QTRLY LOSS PER SHARE $0.31.DATA READOUTS FROM FIVE ONGOING LATE-STAGE TRIALS EXPECTED IN 2019.Q3 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.MINERVA NEUROSCIENCES - RESEARCH AND DEVELOPMENT EXPENSES EXPECTED TO RISE DURING 2018 IN CONNECTION WITH ROLUPERIDONE AND MIN-117 CLINICAL TRIALS.G&A EXPENSES ARE EXPECTED TO INCREASE DURING 2018.  Full Article

Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder
Monday, 9 Apr 2018 08:30am EDT 

April 9 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER.117 ARE EXPECTED IN FIRST HALF OF 2019.  Full Article

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter And Year End Financial Results
Monday, 12 Mar 2018 07:30am EDT 

March 12 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES REPORTS FISCAL 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES.Q4 EARNINGS PER SHARE $0.00.Q4 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.MINERVA NEUROSCIENCES - SEES EXISTING CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO MEET ANTICIPATED CAPITAL REQUIREMENTS FOR AT LEAST NEXT 12 MONTHS.MINERVA NEUROSCIENCES - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2017 WERE ABOUT $133.2 MILLION.  Full Article

Minerva Neurosciences Names Remy Luthringer As Executive Chairman
Monday, 5 Feb 2018 08:30am EST 

Feb 5 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR.SAYS CHAIRMAN OF THE BOARD MARC BEER RESIGNED.MINERVA NEUROSCIENCES - WILLIAM DOYLE IS EXECUTIVE CHAIRMAN OF NOVOCURE.  Full Article

Minerva Neurosciences Names Remy Luthringer As Executive Chairman
Monday, 5 Feb 2018 08:30am EST 

Feb 5 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR.MINERVA NEUROSCIENCES INC - MARC BEER HAS RESIGNED AS CHAIRMAN OF MINERVA'S BOARD OF DIRECTORS.  Full Article

Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2B Trial Comparing Seltorexant Versus Quetiapine
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2B TRIAL COMPARING SELTOREXANT (MIN-202) VERSUS QUETIAPINE AS ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.MINERVA NEUROSCIENCES INC - ‍ TOP-LINE RESULTS FROM 12-WEEK DOUBLE BLIND PHASE OF TRIAL OF MIN-101 ARE EXPECTED IN FIRST HALF OF 2019​.  Full Article

Minerva Neurosciences names Richard Russell president
Monday, 11 Dec 2017 04:41pm EST 

Dec 11 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT.MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT.  Full Article